---
document_datetime: 2025-05-23 19:27:43
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/advate-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: advate-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5042806
conversion_datetime: 2025-12-27 09:20:02.374004
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Advate

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 21/05/2025                          |                                             | SmPC, Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000254887                     | PRODUCTS - C.I.z Other variation - Accepted C.I.z - To update sections 4.2, 4.4, 4.5 and 4.8 of the SmPC to implement the recommendation of the CHMP based on Core SmPC for human plasma derived and recombinant coagulation factor VIII (Revision 3) products. In addition, the following changes are proposed as editorial within this variation application: · Combining the current 10 SmPCs into two: one SmPC for presentations with 2ml diluent and one for those with 5ml diluent in line with QRD recommendations. · The MAH is proposing to include the volume of dilution in the product name (eg. 250 IU/5 ml). · Update in line with the Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017- 11668) - Revision 4, regarding polysorbates. · Updates in line with guidelines for product information, including the current QRD template v10.4. · Minor rewording or reordering of text in order to enhance   |            |     | II, Labelling and PL   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| Variation type II / EMA/VR/0000256654 | B.II.g) Design Space and post approval change management protocol - B.II.g.2 Introduction of a post approval change management protocol related to the finished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 15/05/2025 | N/A |                        |

<div style=\"page-break-after: always\"></div>

| product - Accepted   |
|----------------------|